The US FDA has scheduled an Antimicrobial Drugs Advisory Committee (AMDAC) meeting for Thursday, June 9, 2016 to discuss a biologics license application (BLA 761046) for bezlotoxumab for the proposed indication of the prevention of Clostridium difficile (C. diff) infection recurrence.
See the SAC Tracker report